Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
86 hedge funds and large institutions have $101M invested in Cascadian Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 16 closing their positions.
535% more call options, than puts
Call options by funds: $1M | Put options by funds: $158K
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
0% more funds holding
Funds holding: 86 → 86 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
23% less capital invested
Capital invested by funds: $131M → $101M (-$30.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.93M |
| 2 |
DM
Deerfield Management
New York
|
+$5.74M |
| 3 |
BC
Broadfin Capital
New York
|
+$3.82M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$3.19M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$7.72M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.42M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$790K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$784K |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$588K |
CASC Hedge Fund Activity: Q3 2014 in Review
86 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q3 2014, worth a combined $101M — down 23% from $131M a quarter earlier.
Fund positioning in CASC was balanced in Q3 2014: 16 funds opened new positions, 16 closed out, 33 added to existing stakes and 20 trimmed.
The largest buyer was Great Point Partners, adding an estimated $7.93M. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $7.72M sold.
- 86 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $101M of Cascadian Therapeutics, Inc. stock for Q3 2014, down 23% quarter-over-quarter.
- 16 funds opened new Cascadian Therapeutics, Inc. positions in Q3 2014 and 16 closed out, a net change of 0 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q3 2014 was Great Point Partners, an estimated $7.93M added.
- The largest Cascadian Therapeutics, Inc. seller in Q3 2014 was First Eagle Investment Management, an estimated $7.72M sold.
Based on aggregated 13F filings for Q3 2014.